[HTML][HTML] NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage

W Xiong, AEMC Garfinkel, Y Li… - The Journal of …, 2015 - Am Soc Clin Investig
W Xiong, AEMC Garfinkel, Y Li, LI Benowitz, CL Cepko
The Journal of clinical investigation, 2015Am Soc Clin Investig
Oxidative stress contributes to the loss of neurons in many disease conditions as well as
during normal aging; however, small-molecule agents that reduce oxidation have not been
successful in preventing neurodegeneration. Moreover, even if an efficacious systemic
reduction of reactive oxygen and/or nitrogen species (ROS/NOS) could be achieved,
detrimental side effects are likely, as these molecules regulate normal physiological
processes. A more effective and targeted approach might be to augment the endogenous …
Oxidative stress contributes to the loss of neurons in many disease conditions as well as during normal aging; however, small-molecule agents that reduce oxidation have not been successful in preventing neurodegeneration. Moreover, even if an efficacious systemic reduction of reactive oxygen and/or nitrogen species (ROS/NOS) could be achieved, detrimental side effects are likely, as these molecules regulate normal physiological processes. A more effective and targeted approach might be to augment the endogenous antioxidant defense mechanism only in the cells that suffer from oxidation. Here, we created several adeno-associated virus (AAV) vectors to deliver genes that combat oxidation. These vectors encode the transcription factors NRF2 and/or PGC1a, which regulate hundreds of genes that combat oxidation and other forms of stress, or enzymes such as superoxide dismutase 2 (SOD2) and catalase, which directly detoxify ROS. We tested the effectiveness of this approach in 3 models of photoreceptor degeneration and in a nerve crush model. AAV-mediated delivery of NRF2 was more effective than SOD2 and catalase, while expression of PGC1a accelerated photoreceptor death. Since the NRF2-mediated neuroprotective effects extended to photoreceptors and retinal ganglion cells, which are 2 very different types of neurons, these results suggest that this targeted approach may be broadly applicable to many diseases in which cells suffer from oxidative damage.
The Journal of Clinical Investigation